Activity Dates: 09/04/2020 - 09/04/2021
You will proceed through the following steps to satisfactorily complete this course:
Participants in this course must complete an examination and achieve a score of 70% or greater. Up to two exam attempts are provided to each participant. Successful completion of the course also requires the completion of a course evaluation. Upon successful completion, ACPE credit is reported within 24 hours to CPE Monitor although transcripts can be retrieved by participants online in their ACPE Transcript.
CPNP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access CPNP course materials online, you will need:
CPNP web sites no longer fully support Microsoft Internet Explorer 9 and older or Windows 7 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Christoph U. Correll, MD (Activity Chair)
Stella J. Logan APRN, PMHCNS-BC, PMHNP-BC
Leigh Anne Nelson, PharmD, BCPP
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Susan Gitzinger, PharmD, MPA–has no relevant financial relationships to disclose in relation to the content of this activity.
Steve Stoner, PharmD, BCPP–has disclosed that he is on the speakers’ bureau for Neurocrine.
Andrew Cutler, MD-has disclosed that he is a consultant for Alkermes, IntraCellular Therapies, Janssen, Lundbeck, Otsuka, and Sunovion; he receives grant/research support from Alkermes IntraCellular Therapies Janssen, Lundbeck, Otsuka, and Sunovion. He also is a member of the speakers’ bureau for Alkermes, IntraCellular Therapies, Janssen, Lundbeck, Otsuka, and Sunovion.
Deanna Kelly, PharmD, BCPP–has disclosed that she is consultant for Alkermes.
Amanda Simonton, ARNP–has disclosed that she is on a Medscape Education Steering Committee that is supported by grant money from Alkermes.
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). The opinions expressed in the educational activity do not necessarily represent the views of CPNP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
It is the policy of CPNP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CPNP for any product or manufacturer identified.